Quick Answer
CG Oncology, Inc. reported Stockholders Equity of $752.60 million for fiscal year 2025.
CG Oncology, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $752.60M | +2.6% |
| 2024 | $733.38M | +695.8% |
| 2023 | -$123.10M | -58.4% |
| 2022 | -$77.69M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $687.64M | +28.1% | +2.6% |
| June 30, 2025 | $670.36M | +21.4% | -4.9% |
| March 31, 2025 | $704.76M | +23.9% | -3.9% |
| December 31, 2024 | $733.38M | +695.8% | +36.6% |
| September 30, 2024 | $536.77M | +598.9% | -2.8% |
| June 30, 2024 | $552.36M | +667.2% | -2.9% |
| March 31, 2024 | $568.94M | +760.7% | +562.2% |
| December 31, 2023 | -$123.10M | -58.4% | -14.4% |
- CG Oncology, Inc. showed an increase of +2.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, CG Oncology, Inc.’s stockholders equity has grown by 1068.7% (from -$77.69 million to $752.60 million).
- The most recent figure is from CG Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: